hemoglobinopathies diseases affecting the structure, function or production of hb
TRANSCRIPT
Types
1- Structural Hemoglobinopathies A- Abnormal Hb polymerization --- Sickle
cell anemia B- Altered O2 affinity --- High affinity –
polycythemia --- Low affinity – Cyanosis, pseudo
anemia C- Hb that oxidize readily
--- Unstable Hb (HA, jaundice) --- MetHb (cyanosis)
2 -Thalassemia)defective biosynthesis of globin chains (
A- α-thalassemia
B- β-thalassemia
C- δβ, γδβ, αβ thalassemias
3 -Thalassemic Hb variants )structurally abnormal Hb associated with co-
inherited thalassemic phenotype (
A- Hb-E
B- Hb - Constant spring
C- Hb- Lepore
5 -Acquired Hemoglobinopathies A- Met-Hb due to toxic exposure .
B- Sulf-Hb due to toxic exposure .
C- CarboxyHb due to CO .
D- Hb-H in erythroleukemia .
E- Elevated Hb-F in states of erythroid stress & BM dysplasia.
Thalassemia This is an inherited disorder of α or β globin chain
biosynthesis .
Causes reduced production of Hb tetramers causing hypochromia µcytosis. The latter is leading to ineffective erythropoiesis & hemolytic anemia.
Normal Hb consists of 2α and 2β chains .
Two clusters of genes encode for globin synthesis (β genes on chromosome 11 & α genes on
chromosome 16) .
An unbalanced accumulation of α or β chains results
α- Thalassemia Decreased α-chain production relative to β-chain production forming β4 (Hb-H
inclusion bodies) .
RBCs bearing inclusion bodies are rapidly removed from the circulation by RES cells
thus shortening RBC survival.
S & S Deletion of 1 gene (-α/αα) & 2 genes (-/αα; -α/-
α) are virtually asymptomatic .
Deletion of 3 genes (--/-α) producing Hb H disease (Hb Barts).
Moderate hypochromic microcytic anemia & splenomegaly .
Hb= 8-10 g/dL, special stain shows Hb H inclusions .
Hb electrophoresis shows Hb H. Hb H tends to precipitate during oxidative stress & under increased temperature as
in infections causing hemolysis.
Deletion of 4 genes (--/--) is the most severe form that is incompatible with life leading to intrauterine death of the fetus (hydrops
fetalis).
β- Thalassemia Decrease in β-chain production relative to α-
chain production .
Common in Mediterranean, Asian & African populations (areas endemic with malaria) .
Trait --- asymptomatic .
Clinical anemia ---- is seen in homozygous or compound heterozygous e.g. β
thalassemia/Hb E.
Reduced β globin chain synthesis leads to accumulation of free α globin chains that precipitate in early erythroblast
development since they are insoluble .
These lead to ineffective erythropoiesis in BM & enhanced destruction in circulation.
Anemia, splenomegaly ± hypersplenism, osteoporosis, skeletal & soft tissue changes due to BM expansion, iron overload ( ↑GIT absorption & blood transfusion) deposit in liver, heart, pancreas, pituitary & other
endocrine organs.
Lab. Dx Microcytic hypochromic anemia, MCV.↓
Hb- electrophoresis --- Hb A2 ↑ > 4-6%, Hb F ↑ 5-20%.
PCR, DNA probes .
Antenatal Dx --- Amniotic fluid analysis & chorionic villous sampling.
℞
α-thalassemia ---- 1 gene or 2 genes deletion may be asymptomatic and
require no treatment .
Hb H disease- Folic acid 1mg/day orally
Splenectomy for progressive anemia.
β thalassemia Improved outcome recently due to the use of aggressive blood transfusion support &
effective iron chelation therapy .
The only curative ttt by BM transplantation.
Blood transfusion –non-transfused pt survives only 2 y in
homozygous state . -- Aim to maintain Hb at 11-13g/dL
-- Pre-transfusion level>10g/dL -- extend life to 2nd decade, minimize
bony abnormalities, and improve sexual development .
-- Leukocyte-poor RBCs given to minimize allosenstization & not to prejudice
future BMT . -- HB vaccine given for pt with –ve Ab test
Splenectomy if transfusion requirement > 1.5 normal (>200ml/kg/year)
-- preceded by polyvalent pneumococcal vaccine (pediatric pt also given H influenza & N meningitides vaccine)
Iron chelation ---if not given pts will die of iron overload .
--- Subcutaneous desferrioxamine 1.5-2.5 g/d
--- Oral defroperone, deferasirox
--- S.C desferral 12-24 h infusion 5-6x/w --- S/E visual disturbances, tinnitus, azotemia,
proteinuria .
Annual ophth & audiol exam needed.
---Periodic estimation of iron burden (S Fe, TIBC & S Ferritin)
--- Estimate of liver iron concentration
--- Annual cardiac evaluation to detect early dis
--- GTT, thyroid function test, cortisol determination
--- Hormone replacement therapy
Manipulation of globin chain gene expression with
5-azacytidine, hydroxyurea, erythropoietin ,
butyrate analogues to stimulate Hb F synthesis by γ globin chain augmentation